Payment overview · 2025
General Payments
$257.37
11 reported records · 5 companies
Healthcare provider profile · identity verified
Hector Perez, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · NEW YORK, NY · NPI 1851415426
Verified facts
What the public records show
CMS Open Payments records show Hector Perez, M.D. received $257.37 in general payments during 2025 across 11 reported records.
PFIZER INC. accounted for 46.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 146 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $119.91 | 46.6% | 6 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $44.68 | 17.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $36.30 | 14.1% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $30.18 | 11.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $26.30 | 10.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $257.37 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $119.91 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $119.91 | 6 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $44.68 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $36.30 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $30.18 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $26.30 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 46 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 146 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
146 | 36 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
46 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 796 | 250 |
| Metformin Hcl | Metformin Hcl | 713 | 216 |
| Atorvastatin Calcium | Atorvastatin Calcium | 659 | 210 |
| Amlodipine Besylate | Amlodipine Besylate | 548 | 180 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 491 | 144 |
| Omeprazole | Omeprazole | 427 | 142 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 359 | 117 |
| Gabapentin | Gabapentin | 294 | 109 |
| Lisinopril | Lisinopril | 260 | 90 |
| Metoprolol Succinate | Metoprolol Succinate | 242 | 75 |
| Glipizide Er | Glipizide | 215 | 59 |
| Enalapril Maleate | Enalapril Maleate | 199 | 60 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 197 | 83 |
| Carvedilol | Carvedilol | 194 | 61 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 157 | 44 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 152 | 49 |
| Levothyroxine Sodium | Levothyroxine Sodium | 151 | 46 |
| Fluticasone Propionate | Fluticasone Propionate | 148 | 77 |
| Ozempic | Semaglutide | 146 | 36 |
| Januvia | Sitagliptin Phosphate | 145 | 48 |
| Meloxicam | Meloxicam | 145 | 64 |
| Tamsulosin Hcl | Tamsulosin Hcl | 139 | 47 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 137 | 34 |
| Famotidine | Famotidine | 132 | 43 |
| Losartan Potassium | Losartan Potassium | 125 | 43 |
| Prednisone | Prednisone | 117 | 91 |
| Montelukast Sodium | Montelukast Sodium | 116 | 40 |
| Ibuprofen | Ibuprofen | 95 | 27 |
| Single Use Swab | Alcohol Antiseptic Pads | 94 | 35 |
| Furosemide | Furosemide | 93 | 30 |
| Jardiance | Empagliflozin | 90 | 19 |
| Linzess | Linaclotide | 89 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 89 | 27 |
| Meclizine Hcl | Meclizine Hcl | 85 | 35 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 84 | 46 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 83 | 25 |
| Mirtazapine | Mirtazapine | 81 | 28 |
| Valsartan | Valsartan | 76 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 75 | 24 |
| Simvastatin | Simvastatin | 75 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 71 | 19 |
| Trulicity | Dulaglutide | 67 | 11 |
| Ibandronate Sodium | Ibandronate Sodium | 66 | 17 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 61 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 59 | 26 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 58 | 17 |
| Nifedipine Er | Nifedipine | 55 | 17 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 51 | 21 |
| Atenolol | Atenolol | 50 | 15 |
| Ammonium Lactate | Ammonium Lactate | 49 | 13 |
| Ezetimibe | Ezetimibe | 49 | 15 |
| Naproxen | Naproxen | 48 | 21 |
| Eliquis | Apixaban | 46 | 16 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 45 | 14 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 44 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 42 | 15 |
| Xarelto | Rivaroxaban | 39 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | suppressed |
| Levofloxacin | Levofloxacin | 36 | 33 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 35 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 34 | 12 |
| Farxiga | Dapagliflozin Propanediol | 33 | 15 |
| Levetiracetam | Levetiracetam | 33 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 30 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 24 |
| Glipizide Xl | Glipizide | 29 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 28 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 28 | suppressed |
| Novolog Flexpen | Insulin Aspart | 28 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 26 | suppressed |
| True Comfort Pro Alcohol Pads | Alcohol Antiseptic Pads | 24 | suppressed |
| Entresto | Sacubitril/Valsartan | 23 | suppressed |
| Latanoprost | Latanoprost | 23 | 11 |
| Memantine Hcl Er | Memantine Hcl | 23 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 22 | 12 |
| Finasteride | Finasteride | 22 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 19 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 18 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 17 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 16 | suppressed |
| Terconazole | Terconazole | 16 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Spironolactone | Spironolactone | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Praluent Pen | Alirocumab | 14 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Lumigan | Bimatoprost | 13 | suppressed |
| Procto-Med Hc | Hydrocortisone | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 11 | suppressed |
| Allopurinol | Allopurinol | 11 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 11 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 11 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $257.37 · 11 records | PFIZER INC. | CAPVAXIVE, Cologuard Collection Kit, ELIQUIS, FUROSCIX, NURTEC ODT, Ozempic | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error